Logos Global Management’s Praxis Precision Medicines PRAX Stock Holding History

Logos Global Management’s Portfolio PRAX Stock Details PRAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$87M	Sell	260,000 -25,000	-9%	-$7.91M	3.75%	8
2026 Q1	$91.8M	Sell	285,000 -90,000	-24%	-$27.8M	4.58%	4
2025 Q4	$111M	Buy	375,000 +250,000	+200%	+$46.6M	6.68%	2
2025 Q3	$6.63M	Sell	125,000 -100,000	-44%	-$4.85M	0.59%	44
2025 Q2	$9.46M	Buy	+225,000	New	+$8.57M	1.05%	30
2024 Q2	–	Sell	-150,000	Closed	-$9.15M	–	71
2024 Q1	$9.15M	Buy	+150,000	New	+$6.73M	0.74%	36

Other funds holding PRAX

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Logos Global Management's PRAX Position: Q2 2026 in Review

Logos Global Management reduced its Praxis Precision Medicines (PRAX) stake by 8.8% in Q2 2026, selling an estimated $7.91M and leaving 260,000 shares worth $87M. The position accounts for 3.75% of the portfolio, ranked #8.

Logos Global Management first reported a position in PRAX in Q1 2024 and has held it in 6 quarters since. The position peaked at $111M in Q4 2025. 309 funds tracked by Wall St. Rank hold PRAX as of Q2 2026.

Logos Global Management held 260,000 shares of Praxis Precision Medicines worth $87M as of Q2 2026.
Logos Global Management sold 25,000 Praxis Precision Medicines shares in Q2 2026, an estimated $7.91M.
Praxis Precision Medicines made up 3.75% of Logos Global Management's portfolio in Q2 2026, its #8 holding.
Logos Global Management first reported a position in Praxis Precision Medicines in Q1 2024 and has held it in 6 quarters since.
Logos Global Management's Praxis Precision Medicines position peaked at $111M in Q4 2025.
309 funds tracked by Wall St. Rank held Praxis Precision Medicines as of Q2 2026.

Based on Logos Global Management's 13F filing for Q2 2026, filed 14 Aug 2026.